About this episode
In The Tox Talks we feature expert injectors with significant experience using botulinum toxins. We explore their experience with particular brands, how their techniques have evolved and the subtle nuances of getting the best out of toxins.
In Chapter 3 we tackle the poorly understood topic of toxin resistance. In one of our most engaging episodes to date, Dr Stefania Roberts and Dr Niamh Corduff debate what we mean by resistance, whether it differs from being a non-responder, primary versus secondary non-responders, and why the incidence is so hard to quote.
We cover how Botox (Allergan) is manufactured and how that differs from Xeomin (Merz), accessory proteins and the immune response, neutralising versus non-neutralising antibodies, whether higher doses or more frequent treatments raise the risk, how to review a patient whose toxin didn't work, whether to switch brands, the post-lockdown wave of 'failed' treatments and what testing is available for true primary non-responders.
What you'll learn
- Primary versus secondary non-responders
- How antibodies and accessory proteins are involved
- Whether dose and frequency increase the risk
- How to review a patient whose toxin didn't work
- Whether switching toxin brands helps
Topics
- The Tox Talks
- Botulinum toxin
- Toxin resistance
- Merz
- Australia
Full transcript
The full transcript for this episode is coming soon.